ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 85 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $0 | – | 248 | 0.0% | 0.00% | – |
| Q1 2024 | $0 | – | 248 | 0.0% | 0.00% | – |
| Q4 2023 | $0 | -100.0% | 248 | 0.0% | 0.00% | – |
| Q3 2023 | $2 | -33.3% | 248 | 0.0% | 0.00% | – |
| Q2 2023 | $3 | +50.0% | 248 | 0.0% | 0.00% | – |
| Q1 2023 | $2 | -50.0% | 248 | 0.0% | 0.00% | – |
| Q4 2022 | $4 | -99.9% | 248 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | +33.3% | 248 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | 0.0% | 248 | +38.5% | 0.00% | – |
| Q1 2022 | $3,000 | 0.0% | 179 | 0.0% | 0.00% | – |
| Q4 2021 | $3,000 | – | 179 | +5.3% | 0.00% | – |
| Q3 2019 | $0 | – | 170 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | -100.0% | 170 | 0.0% | 0.00% | – |
| Q1 2019 | $1,000 | 0.0% | 170 | 0.0% | 0.00% | – |
| Q4 2018 | $1,000 | -50.0% | 170 | 0.0% | 0.00% | – |
| Q3 2018 | $2,000 | -33.3% | 170 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | 0.0% | 170 | 0.0% | 0.00% | – |
| Q1 2018 | $3,000 | – | 170 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,808,034 | $29,119,313 | 14.32% |
| Foresite Capital Management V, LLC | 1,258,243 | $13,047,980 | 9.53% |
| GREAT POINT PARTNERS LLC | 1,941,581 | $20,134,195 | 3.94% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $35,258,000 | 3.63% |
| Aisling Capital Management LP | 434,455 | $4,505,298 | 2.21% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 651,400 | $6,755,018 | 2.09% |
| VR Adviser, LLC | 1,040,754 | $10,792,619 | 1.73% |
| Ikarian Capital, LLC | 796,300 | $8,257,631 | 1.32% |
| Samsara BioCapital, LLC | 696,171 | $7,219,293 | 1.27% |
| BRAIDWELL LP | 2,901,194 | $30,085,382 | 0.98% |